TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06200402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic loaded
Description: This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04876937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
Study: NCT04079582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).
Description: (Dialysate magnesium concentration currently used in Canada and the United States)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).
Description: (Dialysate magnesium concentration currently used in Canada and the United States)
Study: NCT05161195

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: Participants continue ribociclib in combination with anastrozole as was administered in their parent study

Intervention type: DRUG
Group type: OTHER
Intervention: Goserelin
Description: Participants continue ribociclib in combination with goserelin as was administered in their parent study
Study: NCT05868993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose of 0.5% Ropivacaine
Description: Dose varied by 5mL of 0.5% Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose of 0.5% Ropivacaine
Description: Dose varied by 5mL of 0.5% Ropivacaine
Study: NCT03926819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBI-002
Description: Oral liquid carbon monoxide drug product.
Study: NCT05161195

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: Participants continue ribociclib in combination with tamoxifen as was administered in their parent study

Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant
Description: All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
Study: NCT06554639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5684
Description: Administered via oral tablet per dosing regimen.
Study: NCT05566847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Education
Description: The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
Study: NCT05868993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose of 0.5% Ropivacaine
Description: Dose varied by 5mL of 0.5% Ropivacaine
Study: NCT05767216

Intervention type: OTHER
Group type: OTHER
Intervention: Biological sampling
Description: Blood, skin and stool samples for laboratory analysis
Study: NCT04999696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical hysterectomy
Description: To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy
Description: To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy
Study: NCT04783194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone+ Bupivacaine
Description: Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
Study: NCT05566847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Education
Description: The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accountable Population Manager outreach
Description: Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
Study: NCT04059562

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of Lonsurf® and Irinotecan
Description: Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~* Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~* Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose.
Study: NCT04948671

Intervention type: OTHER
Intervention: there will be no intervention, this is an observational study
Description: this is an observational study

Intervention type: OTHER
Intervention: there will be no intervention, this is an observational study
Description: this is an observational study
Study: NCT06554639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5684
Description: Administered via oral tablet per dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Description: Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Description: Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrocholoride
Description: Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
Study: NCT06554483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: supportive reliable exercise programs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supportive reliable exercise programs
Study: NCT06641414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisaftoclax (APG-2575)
Description: QD, oral administration.
Study: NCT06155682

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (active)
Description: non-invasive active repetitive stimulation applied to the scalp surface

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (sham)
Description: non-invasive active repetitive stimulation applied to the scalp surface
Study: NCT05776576

Intervention type: BEHAVIORAL
Intervention: Evaluation
Description: Within the scope of the evaluation, first of all, physical activity levels of children and adolescents with physical disabilities, barriers that prevent them from participating in physical activity, and motivators that can increase their participation will be determined, accompanied by an interactive roundtable meeting. Afterwards, posture analyzes of children and adolescents with special needs with physical disabilities will be performed by physiotherapists.

Intervention type: BEHAVIORAL
Intervention: Education
Description: In the education part, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after the objective posture assessments, postural disorders of children and adolescents with special needs will be determined and accordingly, posture and ergonomics training will be given to the participants individually.

Intervention type: OTHER
Intervention: Experimentation
Description: In the experimentation part, group exercises, dance therapy programs and technology-supported exercise educations with various technological equipment will be implemented in the company of physiotherapists, taking into account the posture assessments.
Study: NCT06641414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: QD, hypodermic or intravenous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine Injection
Description: QD, hypodermic or intravenous injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: QD, oral administration.
Study: NCT06640972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX-002
Description: Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor
Study: NCT06086639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Occupational Therapy Group Training
Description: In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
Study: NCT05905406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical estimulation
Description: Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical estimulation
Description: Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical estimulation
Description: Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical estimulation
Description: Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec
Study: NCT06206473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mEEG assessment
Description: mEEG assessment (V1) will be performed at the patient's bed within 72 hours of the diagnosis of delirium. The mEEG recording, which lasts approximately 2 hours, will be performed by one of the investigators with expertise in electrophysiological acquisition. This non-invasive assessment consists of placing an EEG net on the scalp of the participants and earphones through which the auditory stimuli will be delivered.
Study: NCT04461106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Marketing Campaign
Description: aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (\<5yrs) and pregnant/lactating women
Study: NCT05916196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoroestradiol
Description: 18F-FES PET/CT
Study: NCT06557694

Intervention type: OTHER
Intervention: Data collection
Description: Data collected included maternal demographics, medication during pregnancy, the gestational week when COVID-19 was diagnosed, antenatal diseases occurring after COVID-19 detection during pregnancy, intrauterine growth retardation (IUGR), small for gestational age (SGA), fetal distress, intrauterine fetal demise (IUFD), intrapartum complications, gestational age (GA) at delivery, mode of delivery, postpartum hemorrhage (PPH), admission to the maternal ICU, birth weight, admission to the NICU, and the indication for NICU hospitalization Pregnancy outcomes included mode of delivery, gestational age at delivery, pre-eclampsia, and postpartum hemorrhage (defined as an estimated blood loss of 1,000 mL or greater).
Study: NCT05507944

Intervention type: DIAGNOSTIC_TEST
Intervention: FeNO measurement
Description: Diurnal measurements before work and at 3 hours after work start.

Intervention type: DIAGNOSTIC_TEST
Intervention: FeNO measurement
Description: Diurnal measurements before work and at 3 hours after work start.
Study: NCT05008913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Adavosertib
Description: Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.
Study: NCT05483816

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VR+TENS
Description: The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VR+TENS
Description: The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality
Study: NCT04831216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Appropriate Food Boxes + Diabetes Education
Description: All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
Study: NCT04687241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Almonertinib
Description: Placebo Almonertinib
Study: NCT05120687

Intervention type: DRUG
Intervention: noncorticosteroid systemic immunomodulatory therapy (NCSIT)
Description: Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
Study: NCT05642169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT+PA
Description: In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CON
Description: This group will not suffer any changes in their lifestyle
Study: NCT06640972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06640686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Inspiratory muscle training for increase strength of inspiratory muscle.
Study: NCT05330572

Intervention type: OTHER
Intervention: No interventions were administered to the patients as a part of this study.
Description: No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.

Intervention type: OTHER
Intervention: No interventions were administered to the patients as a part of this study.
Description: No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.
Study: NCT05165407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg will be intravenously administered on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 250mg will be taken orally once daily continuously
Study: NCT04531839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based collaborative quality improvement
Description: Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
Study: NCT04609761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Privigen Injectable Product (Intravenous Immunoglobulin)
Description: Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
Study: NCT06463405

Intervention type: OTHER
Group type: OTHER
Intervention: Splinted
Description: The investigators will compare splinted versus non-splinted crowns in a randomized design. Whether the crowns will be splinted or not are decided by distant randomization separate from clinicians conducting the trial. Twenty sealed envelopes will be opened where its stands whether the crowns has to be splinted crowns or non-splinted crowns. The implants in the splinted side will have an intermediate titanium abutment and impression will be taken at abutment level, whereas impressions in the non-splinted side will be taken directly at the fixture level. The splinted as well as the non-splinted crowns will be screw-retained and produced in monolithic zirconia. An open-tray technique / (scanning) will be used for both reconstructions.

Intervention type: OTHER
Group type: OTHER
Intervention: Splinted
Description: The investigators will compare splinted versus non-splinted crowns in a randomized design. Whether the crowns will be splinted or not are decided by distant randomization separate from clinicians conducting the trial. Twenty sealed envelopes will be opened where its stands whether the crowns has to be splinted crowns or non-splinted crowns. The implants in the splinted side will have an intermediate titanium abutment and impression will be taken at abutment level, whereas impressions in the non-splinted side will be taken directly at the fixture level. The splinted as well as the non-splinted crowns will be screw-retained and produced in monolithic zirconia. An open-tray technique / (scanning) will be used for both reconstructions.
Study: NCT06362070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DaVinci® Surgical System
Description: Assisted-robotic radical Gastrectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hugo™ RAS System
Description: Assisted-robotic radical Gastrectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versius® Robotic Surgery System
Description: Assisted-robotic radical Gastrectomy
Study: NCT05303363

Intervention type: DEVICE
Intervention: VV-ECMO
Description: VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
Study: NCT05515315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 50-60Gy/25-30f
Study: NCT05338242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time Exposure Feedback
Description: Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
Study: NCT04410042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Given IV
Study: NCT06640686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Inspiratory muscle training for increase strength of inspiratory muscle.
Study: NCT06642285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Invasive Respiratory Support bundle
Description: premature neonates who will receive evidence-based guidelines for prevention of nasal pressure injuries associated with non invasive respiratory support till weaning